AMEGA Biotech is a biotechnology organization with a new vision on the production and commercialization of human biopharmaceuticals aimed at achieving the highest quality standards.
With a focus on competitiveness and time-to-market, structure of AMEGA Biotech allows control of all the manufacturing processes, from the Active Pharmaceutical Ingredient (API) to the Finished Dosage Form.
With a strong development platform and four production sites, AMEGA Biotech develops and produces biosimilars. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer. At present, AMEGA Biotech products are available in markets such as the US, Brazil, Chile, Colombia, Uruguay, Mexico, Paraguay and Venezuela, Middle East (Egypt, Iran, Pakistan, Russia and Ukraine) and Southwest Asia (Singapore and Vietnam).
Parque Austral – Insignia Building M1
Avenida Sargento Cayetano Beliera 3025
B1629WWA | Pilar | Bs.As. | Argentina |
Phone: +54 230 438.5600
info@amegabiotech.com
Francisco Molinari, CEO of Argentina’s most sophisticated biotech group discusses Argentina’s competitiveness in the global biosimilar market, the current constraints limiting innovation in Argentina, and his company’s recent transition from…
What was the vision behind the creation of the umbrella organisation Amega Biotech in 2005? What led you to consider setting up an organisation with this structure, and offering these…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
Florencia Davel, head of LatAm operations for Bristol Myers Squibb (BMS) looks back on a successful four years in position, shaping the regional organisation into a true biopharma player in…
The Head of Viatris Latin America, Patrick Doyle, spoke to PharmaBoardroom about setting up the two-year old company’s Latam affiliate during the pandemic, the decision to focus on specific therapeutic…
Boehringer Ingelheim’s managing director for South America, Dirk van Niekerk, provides an overview of the healthcare climate in South America, the challenges tied to political and economic instability, future opportunities…
Dr Guillermo Chantada, incoming president-elect of the International Society of Paediatric Oncology (SIOP) highlights the progress of paediatric oncology in Latin America and gives a call to arms to the…
See our Cookie Privacy Policy Here
